EUVIMEDEUVIMED entdecken
Crossref

Sex-Disaggregated Analysis of Biology, Treatment Tolerability, and Outcome of Multiple Myeloma in a German Cohort

Annamaria Brioli, Theresa Maria Nägler, Olaposi Yomade, Maria Madeleine Rüthrich, Sebastian Scholl, Jochen J Frietsch, Inken Hilgendorf, Thomas Ernst, Herbert Gottfried Sayer, Andreas Hochhaus, Lars-Olof Mügge, Marie von Lilienfeld-Toal

Oncology Research and Treatment · 2022 · 45 (9) · 494-503

DOI: 10.1159/000525493 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research and Treatment, online erschienen am 15.06.2022. Verfasst von Annamaria Brioli und 11 weiteren Autor:innen. Beteiligte Einrichtung: Klinik für Innere Medizin C, Hämatologie und Onkologie, Transplantationszentrum - Palliativmedizin, Universitätsmedizin Greifswald, Greifswald, Germa…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Multiple Myeloma. Die Arbeit wurde bisher 15-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Multiple myeloma (MM) is a plasma cell disease that affects more men than women. Although there is an obvious imbalance in incidence, knowledge of differences in biology and outcome between the sexes is surprisingly rare.

Methods

We performed a unicentric retrospective analysis of patients with MM treated at a tertiary cancer centre between 2003 and 2018.

Results

We present a sex-disaggregated analysis of the characteristics and outcome of MM in a cohort of 655 patients (median age at diagnosis 62 years; 363 men with a median age at diagnosis 62 years and 292 women with a median age at diagnosis 63 years, p = 0.086). Most patients (n = 561, 86%) received myeloma-specific treatment. Median overall survival was 76 months (95% CI 63–89) (72 months in men [95% CI 54–90] and 83 months in women [95% CI 66–100], p = ns). Apart from a higher incidence of moderate and severe anaemia in women (p < 0.001), there were no statistically significant differences in the biology of the underlying MM. Similarly, in the group of patients who received high-dose therapy with autologous stem-cell transplantation (ASCT, n = 313), no statistically significant differences apart from more frequent anaemia in women were detected regarding the biology of the disease. However, there was a trend toward a higher plasma cell infiltration of the bone marrow and toward more frequent high-risk features in women. In contrast, relevant comorbidities were significantly more common in men (for example, coronary heart disease in 13% of men vs. 2% of women, p < 0.001). Toxicities after ASCT were not significantly different between the sexes with the exception of severe mucositis, which occurred in 22% of men versus 40% of women (p = 0.001).

Conclusion

In conclusion, this first sex-disaggregated analysis of MM patients in Germany supports previous findings that survival is comparable amongst sexes, but women experience more toxicity of high-dose therapy. The higher incidence of clinically relevant anaemia in women warrants further investigation to exclude underlying treatable causes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationMultiple MyelomaBiologyFemaleHumansMaleRetrospective StudiesTransplantation, AutologousTreatment Outcome

Stichwörter der Autor:innen

AnaemiaAutologous stem-cell transplantationMucositisMultiple myelomaSex differences

Autor:innen und Institutionen

  • Klinik für Innere Medizin C, Hämatologie und Onkologie, Transplantationszentrum - Palliativmedizin, Universitätsmedizin Greifswald, Greifswald, Germany.
  • Klinik für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.
  • Klinik für Notfallmedizin, Universitätsklinikum Jena, Jena, Germany.
  • Institut für Medizinische Statistik, Informatik und Datenwissenschaften, Universitätsklinikum Jena, Jena, Germany.
  • Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
  • Helios Klinikum Erfurt, 4. Medizinische Klinik (Hämatologie, Stammzelltransplantation, Onkologie), Erfurt, Germany.

Zitieren

APA

Brioli, A., Nägler, T. M., Yomade, O., Rüthrich, M. M., Scholl, S., Frietsch, J. J., Hilgendorf, I., Ernst, T., Sayer, H. G., Hochhaus, A., Mügge, L. O., & von Lilienfeld-Toal, M. (2022). Sex-Disaggregated Analysis of Biology, Treatment Tolerability, and Outcome of Multiple Myeloma in a German Cohort. Oncology Research and Treatment, 45(9), 494-503. https://doi.org/10.1159/000525493

Vancouver

Brioli A, Nägler TM, Yomade O, Rüthrich MM, Scholl S, Frietsch JJ, et al. Sex-Disaggregated Analysis of Biology, Treatment Tolerability, and Outcome of Multiple Myeloma in a German Cohort. Oncology Research and Treatment. 2022;45(9):494-503. doi:10.1159/000525493

BibTeX
@article{Brioli2022,
  author = {Brioli, Annamaria and Nägler, Theresa Maria and Yomade, Olaposi and Rüthrich, Maria Madeleine and Scholl, Sebastian and Frietsch, Jochen J and Hilgendorf, Inken and Ernst, Thomas and Sayer, Herbert Gottfried and Hochhaus, Andreas and Mügge, Lars-Olof and von Lilienfeld-Toal, Marie},
  title = {Sex-Disaggregated Analysis of Biology, Treatment Tolerability, and Outcome of Multiple Myeloma in a German Cohort},
  journal = {Oncology Research and Treatment},
  year = {2022},
  volume = {45},
  number = {9},
  pages = {494--503},
  doi = {10.1159/000525493}
}
Kostenlos starten →